Skip to main content
Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ARMP ISIN · US04216R1023 LEI · 549300QM1VCWH8KT0S21 US Manufacturing
Open in API
Filings indexed 1,011 across all filing types
Latest filing 2016-11-25 Major Shareholding Noti…
Country US United States of America
Listing US ARMP

About Armata Pharmaceuticals, Inc.

https://www.armatapharma.com/

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat the global threat of antibiotic-resistant infections. The company's core focus is on creating precisely targeted, high-purity phage-based treatments for serious bacterial infections. This approach aims to provide an effective alternative to conventional antibiotics by eliminating harmful bacteria while preserving the patient's healthy microbiome. Armata's pipeline includes product candidates targeting multi-drug resistant pathogens, supported by its in-house cGMP manufacturing facility for clinical and commercial supply.

Recent filings

Filing Released Lang Actions
SC 13G
Major Shareholding Notification
2016-11-25 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated November 17, 2016. It details an underwriting agreement for a public offering of common stock and warrants, including pricing, number of shares, and expected proceeds. The document includes a press release and a warrant form as exhibits. There are no financial statements or detailed financial performance data included, nor is this a full annual or quarterly report. The content focuses on a financing transaction and capital raising activity. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is over 6000 characters, indicating it is not a brief announcement but a substantive filing about financing.
2016-11-17 English
424B4
Capital/Financing Update Classification · 100% confidence The document is a prospectus filed pursuant to Rule 424(b)(4) related to an offering of common stock and warrants. It details the terms of the offering, underwriting, risk factors, business overview, and other information relevant to investors. This type of document is a registration statement prospectus used for capital raising and financing activities. It is not an annual or quarterly report, audit report, earnings release, or any other type of report or announcement. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, consistent with a financing update.
2016-11-17 English
POS EX
Regulatory Filings Classification · 100% confidence The document is a Post-Effective Amendment No. 1 to a Form S-1 Registration Statement filed with the SEC. It relates to the Securities Act of 1933 and involves replacing an exhibit to the original registration statement. The document includes signatures of officers and directors and references legal opinions and powers of attorney. It is not a financial report, earnings release, or management discussion. Instead, it is a regulatory filing related to securities registration and amendments to such filings. The document length is 6849 characters, which is substantive but the content is clearly a regulatory amendment filing rather than a financial report or announcement of a report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2016-11-17 English
Regulatory Filings 2016
Regulatory Filings
2016-11-17 English
FORM 4
Director's Dealing
2016-11-16 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.